Tag: Irukandji Syndrome antidote
Phebra to spearhead clinical trial for Irukandji Syndrome antidote
Australian pharmaceutical company Phebra in collaboration with distinguished experts from around North Queensland will be working on a new clinical trial to test the...
Featured Article
The economic forces driving manufacturing’s next cycle
Australia’s manufacturing sector entered 2026 with improving momentum, but renewed global disruption is again testing resilience across the industry.
